{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:20:35Z","timestamp":1788315635933,"version":"build-2803163510"},"reference-count":28,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":3277,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Even under closed-loop (CL) conditions, meal-related blood glucose (BG) excursions frequently exceed target levels as a result of delays in absorption of insulin from the subcutaneous site of infusion. We hypothesized that delaying gastric emptying with preprandial injections of pramlintide would improve postprandial glycemia by allowing a better match between carbohydrate and insulin absorptions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Eight subjects (4 female; age, 15\u201328 years; A1C, 7.5 \u00b1 0.7%) were studied for 48 h on a CL insulin-delivery system with a proportional integral derivative algorithm with insulin feedback: 24 h on CL control alone (CL) and 24 h on CL control plus 30-\u03bcg premeal injections of pramlintide (CLP). Target glucose was set at 120 mg\/dL; timing and contents of meals were identical on both study days. No premeal manual boluses were given. Differences in reference BG excursions, defined as the incremental glucose rise from premeal to peak, were compared between conditions for each meal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>CLP was associated with overall delayed time to peak BG (2.5 \u00b1 0.9 vs. 1.5 \u00b1 0.5 h; P &amp;lt; 0.0001) and reduced magnitude of glycemic excursion (88 \u00b1 42 vs. 113 \u00b1 32 mg\/dL; P = 0.006) compared with CL alone. Pramlintide effects on glycemic excursions were particularly evident at lunch and dinner, in association with higher premeal insulin concentrations at those mealtimes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Pramlintide delayed the time to peak postprandial BG and reduced the magnitude of prandial BG excursions. Beneficial effects of pramlintide on CL may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-0330","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T09:28:44Z","timestamp":1342776524000},"page":"1994-1999","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":122,"title":["Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes"],"prefix":"10.2337","volume":"35","author":[{"given":"Stuart A.","family":"Weinzimer","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sherr","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda","family":"Cengiz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Carria","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Voskanyan","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Roy","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Northridge, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Tamborlane","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2012,9,11]]},"reference":[{"key":"2022031302371147400_B1","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.2337\/db06-0419","article-title":"Feasibility of automating insulin delivery for the treatment of type 1 diabetes","volume":"55","author":"Steil","year":"2006","journal-title":"Diabetes"},{"key":"2022031302371147400_B2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2337\/dc07-1967","article-title":"Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas","volume":"31","author":"Weinzimer","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2337\/dc09-1080","article-title":"Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas","volume":"33","author":"Renard","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B4"},{"key":"2022031302371147400_B5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2337\/dc09-2254","article-title":"Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes","volume":"33","author":"Castle","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1177\/193229681000400611","article-title":"Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results","volume":"4","author":"Kovatchev","year":"2010","journal-title":"J Diabetes Sci Tech"},{"key":"2022031302371147400_B7","doi-asserted-by":"crossref","first-page":"d1855","DOI":"10.1136\/bmj.d1855","article-title":"Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies","volume":"342","author":"Hovorka","year":"2011","journal-title":"BMJ"},{"key":"2022031302371147400_B8","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00400683","article-title":"Effect of 14 days\u2019 subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM","volume":"39","author":"Kolterman","year":"1996","journal-title":"Diabetologia"},{"key":"2022031302371147400_B10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031302371147400_B11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B12","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type1 diabetes mellitus: a 1-year, randomized, controlled trial","volume":"11","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"2022031302371147400_B14","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031302371147400_B16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"2022031302371147400_B17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"2022031302371147400_B18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman","year":"2002","journal-title":"Metabolism"},{"key":"2022031302371147400_B19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":"The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism"},{"key":"2022031302371147400_B20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"2022031302371147400_B21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","article-title":"The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes","volume":"54","author":"Heptulla","year":"2005","journal-title":"Diabetes"},{"key":"2022031302371147400_B22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1203\/PDR.0b013e318159af8c","article-title":"The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes","volume":"62","author":"Rodriguez","year":"2007","journal-title":"Pediatr Res"},{"key":"2022031302371147400_B23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpeds.2009.03.012","article-title":"Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study","volume":"155","author":"Chase","year":"2009","journal-title":"J Pediatr"},{"key":"2022031302371147400_B24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1399-5448.2008.00490.x","article-title":"Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus","volume":"10","author":"Hassan","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"2022031302371147400_B25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1542\/peds.2008-3750","article-title":"A pilot trial of pramlintide home usage in adolescents with type 1 diabetes","volume":"124","author":"Kishiyama","year":"2009","journal-title":"Pediatrics"},{"key":"2022031302371147400_B26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmpb.2010.06.007","article-title":"Physiologic insulin delivery with insulin feedback: a control systems perspective","volume":"102","author":"Palerm","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"2022031302371147400_B27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2010-2578","article-title":"The effect of insulin feedback on closed loop glucose control","volume":"96","author":"Steil","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031302371147400_B28","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-0545","article-title":"Translating the A1C assay into estimated average glucose values","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/35\/10\/1994\/609376\/1994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/35\/10\/1994\/609376\/1994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:53:16Z","timestamp":1647154396000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/35\/10\/1994\/38549\/Effect-of-Pramlintide-on-Prandial-Glycemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,11]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,9,11]]},"published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-0330","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,11]]}}}